# Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX

> **NCT00749476** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **BIOLOGICAL:** Factor IX recovery

## Key facts

- **NCT ID:** NCT00749476
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00749476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00749476, "Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00749476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*